Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity
Source: SeekingAlpha
2026-01-15 08:49:10 ET
...
Read the full article on Seeking Alpha
For further details see:
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity
Stoke Therapeutics Inc.
NASDAQ: STOK
STOK Trading
12.4% G/L:
$37.76 Last:
279,957 Volume:
$35.60 Open:
STOK Latest News
March 04, 2026 05:06:00 pm
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
February 24, 2026 04:01:00 pm
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
February 11, 2026 07:30:00 am
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
February 04, 2026 04:01:00 pm
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
STOK Stock Data
$1,859,163,232
44,494,260
1.78%
51
N/A
Biotechnology & Life Sciences
Healthcare
US
Bedford
